β-Blockade and increased dyslipidemia in patients bearing Glu27 variant of β2 adrenergic receptor gene

G. Iaccarino, V. Trimarco, F. Lanni, E. Cipolletta, R. Izzo, O. Arcucci, N. De Luca, G. Di Renzo

Research output: Contribution to journalArticle

Abstract

In this study, the effects of polymorphisms of the β2 and β3 adrenergic receptor genes on the occurrence of dyslipidemia and diabetes mellitus in hypertensive patients treated with β-blockers (atenolol or metoprolol) were evaluated. Patients who gave written informed consent were asked to return for blood sampling for estimation of serum glucose, total cholesterol, HDL, triglycerides and for genotype determination. Genotyping analysis was performed by PCR-RFLP assay. In patients bearing β2AR Glu27 or the β3AR Arg64 variant there was a larger occurrence of hypertriglyceridemia, alone or in combination with elevated cholesterol levels. Furthermore, the β2AR Glu27 variant significantly associates with hypetriglyceridemia in a cumulative fashion. The risk to develop this side effect after β-blockade was four-fold higher in patients homozygous for the β2AR Glu27 variant as compared to β2AR27Gln allele. This result allows the identification of patients at high risk to develop metabolic complications to chronic β-blockade treatment.

Original languageEnglish
Pages (from-to)292-297
Number of pages6
JournalPharmacogenomics Journal
Volume5
Issue number5
DOIs
Publication statusPublished - 2005

Fingerprint

Dyslipidemias
Adrenergic Receptors
Genes
Metoprolol
Atenolol
Hypertriglyceridemia
Hypercholesterolemia
Informed Consent
Restriction Fragment Length Polymorphisms
HDL Cholesterol
Diabetes Mellitus
Triglycerides
Alleles
Genotype
Glucose
Polymerase Chain Reaction
Serum
Therapeutics

Keywords

  • β and β adrenergic receptor variants
  • Diabetes mellitus
  • Hypertriglyceridemia

ASJC Scopus subject areas

  • Pharmacology
  • Molecular Medicine
  • Genetics

Cite this

Iaccarino, G., Trimarco, V., Lanni, F., Cipolletta, E., Izzo, R., Arcucci, O., ... Di Renzo, G. (2005). β-Blockade and increased dyslipidemia in patients bearing Glu27 variant of β2 adrenergic receptor gene. Pharmacogenomics Journal, 5(5), 292-297. https://doi.org/10.1038/sj.tpj.6500324

β-Blockade and increased dyslipidemia in patients bearing Glu27 variant of β2 adrenergic receptor gene. / Iaccarino, G.; Trimarco, V.; Lanni, F.; Cipolletta, E.; Izzo, R.; Arcucci, O.; De Luca, N.; Di Renzo, G.

In: Pharmacogenomics Journal, Vol. 5, No. 5, 2005, p. 292-297.

Research output: Contribution to journalArticle

Iaccarino, G, Trimarco, V, Lanni, F, Cipolletta, E, Izzo, R, Arcucci, O, De Luca, N & Di Renzo, G 2005, 'β-Blockade and increased dyslipidemia in patients bearing Glu27 variant of β2 adrenergic receptor gene', Pharmacogenomics Journal, vol. 5, no. 5, pp. 292-297. https://doi.org/10.1038/sj.tpj.6500324
Iaccarino, G. ; Trimarco, V. ; Lanni, F. ; Cipolletta, E. ; Izzo, R. ; Arcucci, O. ; De Luca, N. ; Di Renzo, G. / β-Blockade and increased dyslipidemia in patients bearing Glu27 variant of β2 adrenergic receptor gene. In: Pharmacogenomics Journal. 2005 ; Vol. 5, No. 5. pp. 292-297.
@article{5895462a49c54df4a8ab4203a6c72848,
title = "β-Blockade and increased dyslipidemia in patients bearing Glu27 variant of β2 adrenergic receptor gene",
abstract = "In this study, the effects of polymorphisms of the β2 and β3 adrenergic receptor genes on the occurrence of dyslipidemia and diabetes mellitus in hypertensive patients treated with β-blockers (atenolol or metoprolol) were evaluated. Patients who gave written informed consent were asked to return for blood sampling for estimation of serum glucose, total cholesterol, HDL, triglycerides and for genotype determination. Genotyping analysis was performed by PCR-RFLP assay. In patients bearing β2AR Glu27 or the β3AR Arg64 variant there was a larger occurrence of hypertriglyceridemia, alone or in combination with elevated cholesterol levels. Furthermore, the β2AR Glu27 variant significantly associates with hypetriglyceridemia in a cumulative fashion. The risk to develop this side effect after β-blockade was four-fold higher in patients homozygous for the β2AR Glu27 variant as compared to β2AR27Gln allele. This result allows the identification of patients at high risk to develop metabolic complications to chronic β-blockade treatment.",
keywords = "β and β adrenergic receptor variants, Diabetes mellitus, Hypertriglyceridemia",
author = "G. Iaccarino and V. Trimarco and F. Lanni and E. Cipolletta and R. Izzo and O. Arcucci and {De Luca}, N. and {Di Renzo}, G.",
year = "2005",
doi = "10.1038/sj.tpj.6500324",
language = "English",
volume = "5",
pages = "292--297",
journal = "Pharmacogenomics Journal",
issn = "1470-269X",
publisher = "Nature Publishing Group",
number = "5",

}

TY - JOUR

T1 - β-Blockade and increased dyslipidemia in patients bearing Glu27 variant of β2 adrenergic receptor gene

AU - Iaccarino, G.

AU - Trimarco, V.

AU - Lanni, F.

AU - Cipolletta, E.

AU - Izzo, R.

AU - Arcucci, O.

AU - De Luca, N.

AU - Di Renzo, G.

PY - 2005

Y1 - 2005

N2 - In this study, the effects of polymorphisms of the β2 and β3 adrenergic receptor genes on the occurrence of dyslipidemia and diabetes mellitus in hypertensive patients treated with β-blockers (atenolol or metoprolol) were evaluated. Patients who gave written informed consent were asked to return for blood sampling for estimation of serum glucose, total cholesterol, HDL, triglycerides and for genotype determination. Genotyping analysis was performed by PCR-RFLP assay. In patients bearing β2AR Glu27 or the β3AR Arg64 variant there was a larger occurrence of hypertriglyceridemia, alone or in combination with elevated cholesterol levels. Furthermore, the β2AR Glu27 variant significantly associates with hypetriglyceridemia in a cumulative fashion. The risk to develop this side effect after β-blockade was four-fold higher in patients homozygous for the β2AR Glu27 variant as compared to β2AR27Gln allele. This result allows the identification of patients at high risk to develop metabolic complications to chronic β-blockade treatment.

AB - In this study, the effects of polymorphisms of the β2 and β3 adrenergic receptor genes on the occurrence of dyslipidemia and diabetes mellitus in hypertensive patients treated with β-blockers (atenolol or metoprolol) were evaluated. Patients who gave written informed consent were asked to return for blood sampling for estimation of serum glucose, total cholesterol, HDL, triglycerides and for genotype determination. Genotyping analysis was performed by PCR-RFLP assay. In patients bearing β2AR Glu27 or the β3AR Arg64 variant there was a larger occurrence of hypertriglyceridemia, alone or in combination with elevated cholesterol levels. Furthermore, the β2AR Glu27 variant significantly associates with hypetriglyceridemia in a cumulative fashion. The risk to develop this side effect after β-blockade was four-fold higher in patients homozygous for the β2AR Glu27 variant as compared to β2AR27Gln allele. This result allows the identification of patients at high risk to develop metabolic complications to chronic β-blockade treatment.

KW - β and β adrenergic receptor variants

KW - Diabetes mellitus

KW - Hypertriglyceridemia

UR - http://www.scopus.com/inward/record.url?scp=27144503123&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=27144503123&partnerID=8YFLogxK

U2 - 10.1038/sj.tpj.6500324

DO - 10.1038/sj.tpj.6500324

M3 - Article

C2 - 16027735

AN - SCOPUS:27144503123

VL - 5

SP - 292

EP - 297

JO - Pharmacogenomics Journal

JF - Pharmacogenomics Journal

SN - 1470-269X

IS - 5

ER -